title: Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth.
abstract: One of the most conserved features of all cancers is a profound reprogramming of cellular metabolism, favoring biosynthetic processes and limiting catalytic processes. With the acquired knowledge of some of these important changes, we have designed a combination therapy in order to force cancer cells to use a particular metabolic pathway that ultimately results in the accumulation of toxic products. This innovative approach consists of blocking lipid synthesis, at the same time that we force the cell, through the inhibition of AMP-activated kinase, to accumulate toxic intermediates, such as malonyl-coenzyme A (malonyl-CoA) or nicotinamide adenine dinucleotide phosphate. This results in excess of oxidative stress and cancer cell death. Our new therapeutic strategy, based on the manipulation of metabolic pathways, will certainly set up the basis for new upcoming studies defining a new paradigm of cancer treatment.
authors.affiliation: 1] IGMM, CNRS, Institut de Génétique Moléculaire de Montpellier, Montpellier, France [2] CNRS, UMR5535, Montpellier, France [3] Université de Montpellier 2, Montpellier, France.
authors.forename: V
authors.initials: V
authors.lastname: Fritz
authors.forename: Z
authors.initials: Z
authors.lastname: Benfodda
authors.forename: C
authors.initials: C
authors.lastname: Henriquet
authors.forename: S
authors.initials: S
authors.lastname: Hure
authors.forename: J-P
authors.initials: JP
authors.lastname: Cristol
authors.forename: F
authors.initials: F
authors.lastname: Michel
authors.forename: M-A
authors.initials: MA
authors.lastname: Carbonneau
authors.forename: F
authors.initials: F
authors.lastname: Casas
authors.forename: L
authors.initials: L
authors.lastname: Fajas
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D054890:Fatty Acid Synthase, Type I / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008297:Male; D008316:Malonyl Coenzyme A / Q000378:metabolism; D008819:Mice, Nude; D058990:Molecular Targeted Therapy / Q000379:methods*; D009249:NADP / Q000378:metabolism; D019255:NADPH Oxidases / Q000378:metabolism; D018384:Oxidative Stress; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D004791:Enzyme Inhibitors; D008316:Malonyl Coenzyme A; D009249:NADP; D019255:NADPH Oxidases; C518729:FASN protein, human; D054890:Fatty Acid Synthase, Type I; D055372:AMP-Activated Protein Kinases